Skip to content
MarketScale
‹ Back to IndustriesHealthcare

When Billing CT Scans, a Little Effort Goes a Long Way

It should come as no surprise that providing a patient’s clinical history can help verify and interpret results from a CT scan. Including as much information as possible when submitting an imaging order seems like an obvious practice, and yet researchers from the University of Chicago Medical Center found that many physicians needed a reminder….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

It should come as no surprise that providing a patient’s clinical history can help verify and interpret results from a CT scan. Including as much information as possible when submitting an imaging order seems like an obvious practice, and yet researchers from the University of Chicago Medical Center found that many physicians needed a reminder. Led by Dr. Saad Ali, the team was able to show that the effort physicians put into writing clinical history reports has benefits not only for the patient, but for the doctor’s own hospital or clinic as well. Interventions implemented by Ali’s team led to payments and reimbursements arriving on average 21 days earlier.

To obtain these results, Ali’s team took a look at their own emergency department and analyzed 1,000 requests for head CT scans. They began by simply analyzing the practices that were common in the department at the time. Not only did poor histories complicate the radiology department’s efforts to interpret results, but they also negatively impacted the hospital’s ability to get reimbursed.

According to their findings, inadequate histories can lead to confusion for the coders and billers. With a high rate of inaccurate billings, the denied claims begin to pile up significantly. Seeing this, the researchers were determined to find a way to rectify the situation. There had been plenty of studies that found poor history practices to impact image interpretation and billing, and yet bad habits still persist.

The team put together a program they called an “intervention.” This primarily involved educating the emergency staff about how to write high quality histories. PowerPoint presentations were displayed in the department with helpful tips reinforcing the concepts outlined in the lectures. After this program, not only did image requisitions for CT scans receive higher scores, but payments and reimbursements arrived a full 21 days earlier on average than they had before Ali and his team stepped in.

Any medical practice can always use some improvements. For some, this might mean improving clinical histories, for others it may just mean ensuring that necessary equipment is on hand to properly care for patients. At CurveBeam, we are constantly pushing ourselves to find new ways to provide our customers with the best in weight-bearing CT technology. Just as our customers seek to provide the best care they can to their patients, we work hard to provide them with the equipment they need to do so. To learn more about CurveBeam, visit our About page.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512